

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John P. Cooke et al.

Title: Enhancement of Vascular Function by Modulation of Endogenous

Nitric Oxide Production or Activity

Appl. No.: 10/618,835

Filing Date: 07/15/2003

Examiner: J. Russel

Art Unit: 1654

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 CFR § 1.56</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Under 37 CFR §§ 1.56 and 1.97(b), Applicants bring to the Examiner's attention the documents on the attached SB/08. This information Disclosure Statement is being filed before the mailing date of a first Office action on the merits for the above-referenced application.

Copies of the listed documents are attached and submitted with the Canadian Office action in CA 2,164,632 dated 02-11-2004 (4 pages) on which they were cited. The Canadian application is the national phase of International Application No. PCT/US94/06203, filed 06-02-1994, an application that claims priority to U.S. Application No. 08/076,312, filed 06-11-1993, now U.S. Pat. No. 5,428,070 and U.S. Application No. 08/184,519, filed 01-21-1994, now abandoned. The '312 application is part of the present application's family, as shown by the underlined portion of the family chain, which is reproduced here: This application is a continuation of Application No. 10/060,252, filed 02-01-2002, now U.S. Pat. No. 6,646,006, which application is a continuation of Application No. 09/930,833, filed 08-15-2001, now U.S. Pat. No. 6,642,208, which application is a continuation of Application No. 09/075,509, filed 05-08-1998, now U.S. Pat. no. 6,337,321, which application is a continuation of

SIPE .



Appln. No. 10/618,835 Atty. Dkt. No. 080618-0237

Application No. 08/556,035, filed 11-09-1995, now U.S. Pat. No. 5,891,459, which application is a continuation-in-part of Application No. 08/336,159, filed 11-08-1994, now abandoned, which application is a continuation-in-part of Application No. 08/076,312, filed 06-11-1993, now U.S. Pat. No. 5,428,070.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP § 609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

04-13-2004

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone:

(202) 672-5569

Facsimile:

(202) 672-5399

By .

Stephen B. Maebius

Attorney for Applicants

Registration No. 35,264

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.	Substitute fo	or form 1449B	/PTO		Complete if Known	OIPE	
	INFORMATI	ON DISCLO	SURE	Application Number	10/618,835	/	
	STATEMEN	T BY APPL	ICANT	Filing Date	07/15/2003		
	Date Submit	tad: April 13	2004	First Named Inventor	John P. Cooke	APR 1 3 2004	
	Date Submit	iteu. April 13	, 2004	Group Art Unit	1654	<u> </u>	
	(use as many s	sheets as ne	cessary)	Examiner Name	J. Russel	de de	
Sheet	1	of	1	Attorney Docket Number	080618-0237	E BARRA	

				U.S. PATENT DOCUMENTS		
Examiner Initials*		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)			_	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
									
									

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁰
	E1	COOKE, JOHN P., et al., "Antiatherogenic Effects of L-Arginine in the Hypercholesterolemic Rabbit," Journal of Clinical Investigation, vol. 90, September 1992, pp. 1168-1172.	
	E2	MARIN, JESUS, et al., "Role of Endothelium-Formed Nitric Oxide on Vascular Responses," <i>General Pharmacology</i> , vol. 21, no. 5, 1990, pp. 575-587.	
	E3	JANSSENS, STEFAN P., et al., "Cloning and Expression of a cDNA Encoding Human Endothelium-derived Relaxing Factor/Nitric Oxide Synthase," <i>Journal of Biological Chemistry</i> , vol. 267, no. 21, July 25, 1992, pp. 14519-14522.	

1182877		
Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.